TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer - Related Studies

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

This study has been completed.

Study NCT00057720. Last updated on January 10, 2008. Information provided by Telik

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Ovarian Neoplasms

2	More general conditions related to this trial
		Adnexal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Neoplasms
		Neoplasms by Site
		Ovarian Diseases
		Urogenital Neoplasms

3	Interventions listed in this trial
		TLK286 HCl for injection
		doxorubicin HCl liposome injection

4	Additional drug interventions recognized in this trial
		Doxorubicin
		Topotecan

5	More general drug interventions related to this trial
		Antibiotics, Antineoplastic
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		Telik